# Optimized-dose Amoxicillin Versus Standard-dose Amoxicillin for Quadruple Therapy in Helicobacter Pylori Eradication

> **NCT05635942** · PHASE4 · COMPLETED · sponsor: **Les Laboratoires des Médicaments Stériles** · enrollment: 88 (actual)

## Conditions studied

- Helicobacter Pylori

## Interventions

- **DRUG:** optimized quadruple therapy
- **DRUG:** standard quadruple therapy

## Key facts

- **NCT ID:** NCT05635942
- **Lead sponsor:** Les Laboratoires des Médicaments Stériles
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-29
- **Primary completion:** 2022-08-30
- **Final completion:** 2022-11-01
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2022-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05635942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05635942, "Optimized-dose Amoxicillin Versus Standard-dose Amoxicillin for Quadruple Therapy in Helicobacter Pylori Eradication". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05635942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*